Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RAPP vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NUVB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 4–4 Matrix Metrics)

NUVB Overall Winner 6-Pillar Tally: RAPP 0 – 5 NUVB (1 Tie) Matrix Metrics: RAPP 4 – 4 NUVB

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPP carries a Unified Composite Score of 50.9/100 (HOLD) at $23.16 (N/M Forward P/E, -838.1% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPP vs NUVB
RAPP NASDAQ
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$23.16
-1.82% 1D
Market Cap $1.4B
TTM Revenue $20M
Forward P/E N/M
Beta / 30D Vol 1.22β · 92% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 56.0 Fund 61.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.6%), weak momentum, RSI 37
RSI-14: 37.1 · SMA20: $24.95 · SMA50: $29.85
NUVB NYSE Head-to-Head Winner
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (RAPP 0 – 5 NUVB)

Columns: Metric · RAPP · NUVB
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 66.7x 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +0.0% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $20M $202M
Market Cap $1.4B $1.3B
3. Profitability & Quality NUVB
Gross Margin N/A 85.8%
Operating Margin -838.1% -61.2%
Net Profit Margin 0.0% -67.4%
Return on Equity (ROE) -33.3% -49.1%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$121M -$108M
Cash Flow Margin N/A -53.6%
Net Cash / Leverage $65M Net Cash $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NUVB
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 106.2% (8th %ile) 65.2% (26th %ile)
Put/Call OI Skew 0.23x (Call-Skewed) 0.24x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPP (4) vs NUVB (4)
Institutional Metric RAPP NUVB Criterion Row Edge
Market Capitalization
Scale
$1.4B $1.3B Larger Scale RAPP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-838.1% -61.2% Higher Margin NUVB
Net Profit Margin
Profitability
0.0% -67.4% Higher Margin RAPP
Return on Equity (ROE)
Capital Efficiency
-33.3% -49.1% Higher ROE RAPP
52-Week Range Position
Momentum
4% ($22–$53) 2% ($4–$10) Stronger Trend RAPP
Beta / 30D Volatility
Risk Regime
1.22β · 92% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
50.9 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$20M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 66.7x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$121M ($65M Net Cash) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPP +6.45 pp
RAPP: -12.7% · NUVB: -19.15%
3M Horizon NUVB +9.26 pp
RAPP: -53.05% · NUVB: -43.79%
6M Horizon NUVB +19.11 pp
RAPP: -38.6% · NUVB: -19.49%
1Y Horizon RAPP +33.01 pp
RAPP: -13.84% · NUVB: -46.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPP vs NUVB. Trailing 12-month operating profitability (RAPP -838.1% vs NUVB -61.2%) and valuation multiples (RAPP N/M vs NUVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RAPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-838.1%
ROE / Fwd P/E-33.3% · N/M
NUVB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$202M
Gross Margin85.8%
Op. Margin-61.2%
ROE / Fwd P/E-49.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPP BREAKDOWN
137d in phase · OBV DISTRIBUTION
Current IV 106.2%
IV Percentile 8th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RAPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $24.00 · IV 96.5%

RAPP Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,400)

Compare $2,400 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 96.5% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $25 / $30 Bull Call Spread

Buy 1x $25C · Sell 1x $30C · 31d

Net Entry $240 Debit
T+5d @ +5% Move +$19 (+8%)
Max Risk / Buffer $240 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $20P / $25-$30C Seagull

Sell 1x $20P · Buy 1x $25/$30C · 31d

Net Entry $180 Debit
T+5d @ +5% Move +$49 (+11.0% RoM)
Max Risk / Buffer -16.7% Put Cushion ($440 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -838.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RAPP vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPP carries a Unified Composite Score of 50.9/100 (HOLD) at $23.16 (N/M Forward P/E, -838.1% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: RAPP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). On trailing 12-month operating scale, RAPP generates $20M in USD-normalized revenue versus $202M for NUVB. In operating R&D and SG&A reinvestment, RAPP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

NUVB screens cheaper on headline valuation multiples. RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 66.7x EV/Revenue (unreported FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPP (-33.3% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPP carries 106.2% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 92% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.